 Following eligibility confirmation, each study participant will undergo two episodes of insulin-induced hypoglycemia with plasma glucose 50 mgdL. Both episodes will be treated with a single subcutaneous injection of G-PenTM glucagon. For the first treatment visit, all subjects will receive a 1 mg dose of G-PenTM glucagon. The investigator will have discretion to repeat this same dose at the second treatment visit or give a 0.5 mg dose of G-PenTM glucagon. A follow-up phone call will be conducted 3-7 days following administration of the final dose of study drug as a safety check. 